Grant of Interim Extension of the Term of U.S. Patent No. 8,858,612; Reducer®, 17315 [2020-06447]

Download as PDF Federal Register / Vol. 85, No. 60 / Friday, March 27, 2020 / Notices for annual determination, thus providing flexibility in responding to salmon management concerns in any given year. Notice of interim Patent term extension. ACTION: II. Method of Collection Notifications are made by at-sea radio or cellular phone transmissions. III. Data OMB Control Number: 0648–0433. Form Number(s): None. Type of Review: Regular submission (extension of a currently approved collection). Affected Public: Business or other forprofit organizations. Estimated Number of Respondents: 40. Estimated Time per Response: 15 minutes. Estimated Total Annual Burden Hours: 10 hours. Estimated Total Annual Cost to Public: $0 in recordkeeping/reporting costs. IV. Request for Comments Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record. Dated: March 24, 2020. Sheleen Dumas, Department PRA Clearance Officer, Office of the Chief Information Officer, Commerce Department. [FR Doc. 2020–06402 Filed 3–26–20; 8:45 am] BILLING CODE 3510–22–P khammond on DSKJM1Z7X2PROD with NOTICES DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No.: PTO–P–2020–0019] Grant of Interim Extension of the Term of U.S. Patent No. 8,858,612; Reducer® United States Patent and Trademark Office, Commerce. AGENCY: VerDate Sep<11>2014 16:28 Mar 26, 2020 Jkt 250001 The United States Patent and Trademark Office has issued an order granting interim extension for a oneyear interim extension of the term of U.S. Patent No. 8,858,612. FOR FURTHER INFORMATION CONTACT: Ali Salimi by telephone at (571) 272–0909; by mail marked to his attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313– 1450; by fax marked to his attention at (571) 273–0909; or by email to ali.salimi@uspto.gov. SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On March 11, 2020, Neovasc Medical Ltd., the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 8,858,612. The patent claims method of use of catheter delivered implantable device, Reducer®. The application for patent term extension indicates that a Premarket Approval Application (PMA) P190035 was submitted to the Food and Drug Administration (FDA) on December 31, 2019. Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory review period will continue beyond the original expiration date of the patent, March 27, 2020, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 8,858,612 is granted for a period of one year from the original expiration date of the patent. SUMMARY: Robert Bahr, Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office. [FR Doc. 2020–06447 Filed 3–26–20; 8:45 am] BILLING CODE 3510–16–P PO 00000 Frm 00012 Fmt 4703 Sfmt 4703 17315 DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. PTO–P–2020–0020] Grant of Interim Extension of the Term of U.S. Patent No. 6,953,476; Reducer® United States Patent and Trademark Office, Commerce. ACTION: Notice of interim patent term extension. AGENCY: The United States Patent and Trademark Office has issued an order granting interim extension under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 6,953,476. FOR FURTHER INFORMATION CONTACT: Ali Salimi by telephone at (571) 272–0909; by mail marked to his attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313– 1450; by fax marked to his attention at (571) 273–0909; or by email to ali.salimi@uspto.gov. SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On March 11, 2020, Neovasc Medical Ltd., the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 6,953,476. The patent claims a catheter delivered implantable device, Reducer®. The application for patent term extension indicates that a Premarket Approval Application (PMA) P190035 was submitted to the Food and Drug Administration (FDA) on December 31, 2019. Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory review period will continue beyond the original expiration date of the patent, March 27, 2020, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. SUMMARY: E:\FR\FM\27MRN1.SGM 27MRN1

Agencies

[Federal Register Volume 85, Number 60 (Friday, March 27, 2020)]
[Notices]
[Page 17315]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06447]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2020-0019]


Grant of Interim Extension of the Term of U.S. Patent No. 
8,858,612; Reducer[supreg]

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of interim Patent term extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting interim extension for a one-year interim extension of 
the term of U.S. Patent No. 8,858,612.

FOR FURTHER INFORMATION CONTACT: Ali Salimi by telephone at (571) 272-
0909; by mail marked to his attention and addressed to the Commissioner 
for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 
22313-1450; by fax marked to his attention at (571) 273-0909; or by 
email to [email protected].

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On March 11, 2020, Neovasc Medical Ltd., the patent owner of 
record, timely filed an application under 35 U.S.C. 156(d)(5) for an 
interim extension of the term of U.S. Patent No. 8,858,612. The patent 
claims method of use of catheter delivered implantable device, 
Reducer[supreg]. The application for patent term extension indicates 
that a Premarket Approval Application (PMA) P190035 was submitted to 
the Food and Drug Administration (FDA) on December 31, 2019.
    Review of the patent term extension application indicates that, 
except for permission to market or use the product commercially, the 
subject patent would be eligible for an extension of the patent term 
under 35 U.S.C. 156, and that the patent should be extended for one 
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory 
review period will continue beyond the original expiration date of the 
patent, March 27, 2020, interim extension of the patent term under 35 
U.S.C. 156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 8,858,612 is granted for a period of one year from the 
original expiration date of the patent.

Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent 
and Trademark Office.
[FR Doc. 2020-06447 Filed 3-26-20; 8:45 am]
 BILLING CODE 3510-16-P